Scleroderma Foundation Research Grant Program
The Scleroderma Foundation is a leading nonprofit supporter of scleroderma research - budgeting an average of $1 million - each year to find the cause and cure of scleroderma.
The Foundation’s Research Grant Funding Program has earned a unique place in the field of Scleroderma research. It is respected by medical researchers and by government health agencies such as National Institutes of Health (NIH) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The program is administered by the Scleroderma Foundation's Board of Directors and staff, and guided by the Foundation's Peer Research Review Committee. This committee, composed of scleroderma medical experts from around the world, helps determine which proposals will be funded each year by reading, critiquing and ranking all applications.
The Scleroderma Foundation wants to foster development of innovative, high-quality research by new and established investigators in fields related to systemic sclerosis (SSc, scleroderma). To accomplish this goal, three distinct research grants are offered: "Scleroderma Foundation New Investigator Grant", the "Scleroderma Foundation Established Investigator Grant," and the Collaborative Research Grant (SCORE).
The Future of Scleroderma Research
Thanks to recent advances in research and treatment, scleroderma patients as a group can now expect to live longer and more productive lives—with increased hope for the future.
A Treatment for Scleroderma, however, remains an elusive goal. Research costs continue to climb. Modern laboratory staff, equipment, and supplies are expensive. Laboratories and clinical research programs must look outside their own facilities for financial support.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of NIH, provides funding for the majority of scleroderma research. Although NIH grants to scleroderma researchers have increased in recent years, scleroderma funding is still a relatively low priority.
The Scleroderma Foundation has a critically important role as catalyst - to fund and to stimulate new research and new ideas. The Foundation is enlisting the support of legislators and other decision makers to establish a higher profile for scleroderma and the needs of patients.
The key to all our efforts - to ensure that productive research moves forward - is the continued generosity of our individual and corporate donors.
http://www.scleroderma.org/site/PageServer?pagename=prof_research#.WBrDpi0rIdU
